List of Excipients in Branded Drug LORATADINE 10 MG

Generic Drugs Containing LORATADINE 10 MG

Company	Ingredient	NDC	Excipient
TIME CAP LABORATORIES INC	loratadine tablets usp, 10 mg	49483-732	LACTOSE MONOHYDRATE
TIME CAP LABORATORIES INC	loratadine tablets usp, 10 mg	49483-732	MAGNESIUM STEARATE
TIME CAP LABORATORIES INC	loratadine tablets usp, 10 mg	49483-732	MICROCRYSTALLINE CELLULOSE 101
TIME CAP LABORATORIES INC	loratadine tablets usp, 10 mg	49483-732	SILICON DIOXIDE
TIME CAP LABORATORIES INC	loratadine tablets usp, 10 mg	49483-732	SODIUM STARCH GLYCOLATE TYPE A

What are the Most Frequently-Used Excipients in LORATADINE 10 MG?

# Of NDCs	Excipient
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 101
1	SILICON DIOXIDE
1	SODIUM STARCH GLYCOLATE TYPE A

Loratadine 10 mg Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Loratadine 10 mg is a mature, widely genericized oral antihistamine with low formulation complexity and limited core-drug patent protection. Commercial value now depends on manufacturing cost, product differentiation, palatability, dosing convenience, retailer access, and combination-product execution rather than molecule-level exclusivity. The strongest opportunities are orally disintegrating tablets, chewable tablets, fast-dissolving products, pediatric liquids, private-label supply, and differentiated allergy combinations.

What is the regulatory and commercial status of loratadine 10 mg?

Loratadine is a second-generation H1 antihistamine indicated for temporary relief of allergic rhinitis symptoms and chronic urticaria. The standard adult dose is 10 mg once daily. The product is available in prescription and over-the-counter markets, with Claritin as the reference consumer brand and numerous generic and store-brand products.

The U.S. product category is mature. Generic competition is established across tablets, chewable tablets, orally disintegrating tablets, and oral liquids. The FDA regulates loratadine OTC products through applicable monograph and labeling requirements, while approved prescription and abbreviated new drug application products remain listed in FDA databases and the Orange Book where applicable.[1,2]

Attribute	Loratadine 10 mg position
Therapeutic class	Second-generation antihistamine
Primary use	Allergic rhinitis and urticaria
Standard adult dose	10 mg once daily
Primary dosage forms	Tablet, chewable tablet, orally disintegrating tablet, oral solution
Reference brand	Claritin
Generic availability	Extensive
Biosimilar exposure	None; loratadine is a small molecule
Core patent risk	Low for new standalone products
Main commercial barriers	Retail access, price, supply reliability, flavor, packaging, differentiation
Key regulatory route	OTC monograph or ANDA/NDA pathway, depending on product and market

What excipients are used in loratadine 10 mg tablets?

Loratadine is a low-dose, poorly water-soluble active pharmaceutical ingredient. A conventional immediate-release tablet normally requires excipients that support content uniformity, powder flow, compaction, disintegration, dissolution, stability, and consumer acceptability.

Common excipient classes include:

Functional requirement	Typical excipient classes	Relevance to loratadine 10 mg
Dilution and tablet mass	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Supports uniform distribution of a low-dose API
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves flow and blend uniformity
Surfactant or wetting aid	Sodium lauryl sulfate, poloxamers	Can improve wetting and dissolution
Sweetener	Sucralose, aspartame, acesulfame potassium, saccharin sodium	Important for chewable and orally disintegrating products
Flavor	Fruit, mint, vanilla, or masking systems	Controls bitterness and improves adherence
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Supports appearance, swallowability, and product identification
Preservative	Sodium benzoate, parabens, potassium sorbate	Relevant mainly to aqueous liquids
Suspending agent	Xanthan gum, cellulose derivatives, carrageenan	Stabilizes pediatric oral suspensions

The formulation objective is not simply to maximize disintegration. Loratadine has low aqueous solubility, so a tablet can disintegrate rapidly without achieving rapid drug dissolution. Particle-size control, wetting, surfactant selection, solid-state control, and granulation design can have a greater effect on performance than disintegrant loading alone.

How should an excipient strategy address loratadine’s low dose and poor solubility?

A 10 mg dose creates a content-uniformity challenge because the active represents a small fraction of total tablet weight. Direct compression is commercially attractive, but it requires controlled API particle size, strong powder-flow characteristics, and a robust blending process.

Direct-compression strategy

Direct compression can reduce manufacturing steps and lower cost. A practical platform may combine:

• Microcrystalline cellulose or mannitol as the principal diluent
• A superdisintegrant such as crospovidone or croscarmellose sodium
• Colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate for lubrication
• A wetting agent where dissolution data justify its use

The main risks are segregation, low-dose blend nonuniformity, tablet capping, lubricant sensitivity, and dissolution variability. Geometric dilution, controlled addition of the API, and in-process blend testing are important controls.

Wet-granulation strategy

Wet granulation can improve blend uniformity and compressibility when the API has poor flow or when the target tablet requires high mechanical strength. It increases process complexity and may introduce moisture or thermal stress. Loratadine product development should therefore include solid-state and impurity monitoring during granulation and drying.

Solubility-enhancement strategy

A commercial formulation may use micronized API, surfactants, amorphous dispersions, co-processing, or alternative particle engineering. These approaches can improve dissolution but may increase cost, regulatory complexity, and stability risk.

A solubility-enhanced platform has the strongest commercial rationale when it enables a meaningful consumer claim, such as faster onset, smaller tablet size, or an orally disintegrating presentation. A formulation that improves dissolution without improving labeling, dosing convenience, or consumer experience may not justify higher cost.

What formulation patents can protect loratadine 10 mg products?

Loratadine’s original active-ingredient exclusivity is no longer the primary commercial barrier. New protection would generally need to focus on formulation, dosage form, manufacturing process, packaging, or a specific therapeutic use.

Potential claim categories include:

1. Orally disintegrating compositions. Claims may cover excipient ratios, porous tablets, taste-masking systems, disintegration time, tablet hardness, or moisture-control packaging.
2. Chewable formulations. Protection may focus on flavor systems, low-grittiness matrices, sugar-free compositions, and acceptable mouthfeel.
3. Liquid formulations. Claims can address solubilization, suspension stability, preservative systems, pH, viscosity, and flavor masking.
4. Fast-dissolution formulations. Claims may cover micronized API, wetting agents, solid dispersions, or defined dissolution profiles.
5. Combination products. Loratadine-pseudoephedrine products may involve layered tablets, modified-release decongestant components, and dose-separation technology.
6. Manufacturing processes. Process patents may protect granulation, coating, particle-size control, or continuous manufacturing.
7. Packaging systems. Moisture-barrier blister packs and unit-dose formats can support product stability, particularly for orally disintegrating tablets.

Patent strength depends on claim breadth, enablement, freedom-to-operate results, prosecution history, and the availability of non-infringing formulation alternatives. A narrow excipient-ratio claim is easier to design around than a broad product-by-process claim, while a clinically meaningful performance limitation can be harder to invalidate or avoid.

When does loratadine 10 mg lose exclusivity?

Loratadine has already lost practical market exclusivity in the United States. Generic manufacturers and private-label suppliers compete on price, packaging, retailer placement, and dosage-form variety.

The relevant exclusivity framework is now product-specific:

Exclusivity category	Current commercial significance
Original molecule patent	Historical; no longer blocks ordinary generic entry
New formulation patent	May affect a specific ODT, chewable, liquid, or combination product
Pediatric exclusivity	Historical or product-specific, not a broad barrier to generic loratadine
OTC monograph status	Supports nonprescription marketing when labeling and conditions are met
Brand trademarks	Continue to protect Claritin branding but not the active ingredient
Trade dress	May affect packaging and consumer recognition

A company entering with a standard 10 mg tablet generally faces commodity economics. A company entering with an ODT, premium chewable, pediatric product, or combination product may obtain greater pricing flexibility but also faces more formulation, regulatory, and supply-chain requirements.

What is the Orange Book status of loratadine products?

The Orange Book identifies approved drug products and certain patent and exclusivity information for products approved under the applicable NDA and ANDA framework.[2] Loratadine is also widely marketed through OTC channels, where the regulatory analysis may depend on the product’s specific approval history and monograph status.

For commercial diligence, the Orange Book should be reviewed for:

• The reference listed drug
• Approved dosage forms and strengths
• Listed patents, if any remain relevant
• Pediatric exclusivity
• Therapeutic-equivalence ratings
• ANDA approvals
• Product discontinuation status

A conventional loratadine 10 mg tablet has limited Orange Book-driven differentiation because multiple therapeutically equivalent products are available. The principal diligence issue is whether a proposed product relies on a specific NDA, an ANDA, an OTC monograph pathway, or a private-label agreement with an approved manufacturer.

How do Paragraph IV challenges affect loratadine 10 mg?

Paragraph IV certifications are relevant when an ANDA applicant seeks approval before expiration of a listed patent and asserts that the patent is invalid, unenforceable, or not infringed. For a mature product such as loratadine 10 mg, Paragraph IV risk is usually concentrated in later-generation dosage forms or combination products rather than the basic immediate-release tablet.

Potential litigation triggers include:

• A new ODT patent listed against a reference product
• A controlled-release loratadine-pseudoephedrine formulation
• A liquid formulation with a narrowly claimed solubilizer system
• A patent covering a specific manufacturing process
• A method-of-use patent tied to a defined patient population or dosing regimen

A generic applicant can also use Paragraph III, a statement that it will not market until patent expiration, or a Section viii statement that it is not seeking approval for a patented method of use. For a standard loratadine 10 mg tablet, ordinary generic competition is more commercially important than Paragraph IV litigation.

What commercial opportunities exist for loratadine 10 mg?

Private-label and retailer supply

The largest near-term opportunity is reliable, low-cost supply for pharmacies, mass retailers, warehouse clubs, and e-commerce channels. The product is suitable for dual sourcing and high-volume contract manufacturing. Margin depends on API procurement, tablet yield, packaging automation, and retailer terms.

Unit-dose blister formats can support travel, convenience, and pharmacy shelf differentiation. Bottles remain lower-cost but face greater exposure to channel price competition.

Orally disintegrating tablets

ODTs can target consumers who have difficulty swallowing or prefer water-free dosing. Mannitol-based systems, taste masking, low friability, and moisture-barrier packaging are central development issues.

The commercial proposition is stronger when the product has:

• Rapid disintegration
• Low mouth residue
• Acceptable sweetness
• Low tablet friability
• Stable performance under humidity
• Packaging that protects each dose

Chewable tablets

Chewables can target children and adults who prefer flavored products. The principal risks are bitterness, grittiness, tablet hardness, and excessive sugar content. Sugar-free formulations may broaden use but require careful management of polyol-related gastrointestinal tolerance and tablet texture.

Pediatric oral liquids

Loratadine oral solution or suspension products can serve pediatric and swallowing-impaired populations. The excipient system must control sedimentation or maintain true solution status, preserve the product, mask bitterness, and remain stable over the labeled in-use period.

Pediatric formulation strategy should avoid unnecessary excipient exposure. Sweeteners, preservatives, alcohol, sodium, and high-osmolality systems can affect product positioning and caregiver acceptance.

Combination products

Loratadine-pseudoephedrine products offer higher revenue per unit than standalone loratadine but introduce regulatory and operational complexity. Pseudoephedrine is subject to retail controls and purchase restrictions in the United States under the Combat Methamphetamine Epidemic Act.[3]

Combination products may use immediate-release or extended-release pseudoephedrine. The formulation must control dose dumping, component release profiles, tablet layering, and consumer labeling. These products compete with cetirizine-pseudoephedrine and fexofenadine-pseudoephedrine combinations.

Geographic expansion

Loratadine is sold in multiple international markets under different regulatory categories. Country-specific opportunities include:

• OTC registration in markets where antihistamines are nonprescription
• Local-language labeling and package adaptation
• Pediatric liquids for markets with limited tablet penetration
• Blister packaging for hot and humid climates
• Low-cost government or institutional supply
• Combination products where local decongestant rules permit them

Patent and regulatory analysis must be performed by country. A U.S. formulation patent does not create global protection, and a product that qualifies for an OTC route in one country may require a full marketing authorization elsewhere.

How does loratadine compare with competing antihistamines?

Product	Commercial position	Formulation opportunity	Key competitive issue
Loratadine 10 mg	Mature, low-cost, broad generic supply	ODT, chewable, liquid, private label	Heavy price competition
Cetirizine 10 mg	Strong OTC presence and broad consumer awareness	Chewable, liquid, combination products	Sedation perception in some users
Fexofenadine 180 mg	Premium positioning in some markets	ODT, high-strength tablets, liquid	Higher dose and brand competition
Desloratadine 5 mg	Active metabolite of loratadine	Specialty dosage forms and pediatric products	Smaller market and generic competition
Diphenhydramine	Older first-generation antihistamine	Nighttime and combination products	Sedation and anticholinergic effects

Loratadine’s main advantage is a familiar once-daily, generally non-sedating profile. Its main disadvantage is limited pricing power. A new product must offer a tangible consumer benefit or a structural supply advantage.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. Standard tablets are relatively easy to produce, but commercial success requires consistent low-dose blend uniformity, dissolution, packaging, and supply continuity.

Higher barriers apply to:

• Moisture-sensitive ODTs
• Taste-masked pediatric liquids
• Solubility-enhanced formulations
• Modified-release combinations
• Low-friability chewables
• High-throughput unit-dose packaging

The most defensible IP strategy combines formulation claims with process controls, stability data, packaging protection, and a distinctive consumer presentation. A patent built only around routine excipient substitution is vulnerable to obviousness challenges and design-around activity.

What generic launch risks exist for loratadine 10 mg?

Generic launch risk is high for an undifferentiated immediate-release tablet because:

• The active ingredient is widely available.
• Multiple manufacturers already supply the market.
• Therapeutic substitution is straightforward.
• Retail buyers have strong purchasing leverage.
• Consumer switching costs are low.
• Brand loyalty is concentrated in Claritin, not in a new generic entrant.

Risk is lower for a differentiated product with proprietary packaging, superior taste, a pediatric indication, a validated fast-disintegration profile, or a reliable supply agreement. Even then, the company must distinguish a real product benefit from a claim that consumers and retailers will not value.

Key Takeaways

• Loratadine 10 mg is a mature generic and OTC market with low standalone patent barriers.
• Excipient selection should prioritize low-dose uniformity, dissolution, disintegration, stability, and palatability.
• ODTs, chewables, pediatric liquids, and private-label supply offer the clearest commercial opportunities.
• Formulation patents can protect dosage-form performance, taste masking, solubility enhancement, manufacturing, or packaging.
• Standard tablets are exposed to severe price competition and should be manufactured at low cost.
• Loratadine-pseudoephedrine combinations can support higher value but carry additional regulatory and supply controls.
• Biosimilar risk does not apply because loratadine is a small-molecule drug.
• A commercially meaningful formulation benefit is more valuable than a narrow excipient substitution claim.

FAQs About Loratadine 10 mg Excipient and Commercial Strategy

What is the best filler for a loratadine 10 mg tablet?

Microcrystalline cellulose, mannitol, lactose, and dibasic calcium phosphate are common candidates. The preferred filler depends on compression, flow, dissolution, moisture sensitivity, tablet size, and dosage form.

Can loratadine 10 mg be formulated as an orally disintegrating tablet?

Yes. An ODT can use a rapidly disintegrating matrix with mannitol, a superdisintegrant, flavor, sweetener, and moisture-protective packaging. Taste masking and tablet friability are the main development risks.

Is loratadine suitable for a pediatric liquid product?

Yes. A pediatric liquid can be developed as a solution or suspension, but the formulation must address bitterness, preservation, dose uniformity, sedimentation, viscosity, and caregiver acceptability.

Does loratadine have biosimilar competition?

No. Biosimilars apply to biological products. Loratadine is a chemically synthesized small molecule and competes through generic drug pathways.

Can a new loratadine formulation obtain patent protection?

Potentially. Protection may be available for a non-obvious ODT, chewable, liquid, solubility-enhanced composition, modified-release combination, manufacturing process, or packaging system. The strongest claims normally require a defined technical feature tied to measurable performance.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act of 2005. https://www.deadiversion.usdoj.gov/
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. U.S. Food and Drug Administration. (n.d.). Loratadine drug labeling and product information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/